Stock GUBRA GUBRA A/S
Add to a list
To use this feature you must be a member
Log inSign up

Financials Gubra A/S

Equities

GUBRA

DK0062266474

Biotechnology & Medical Research

Delayed Nasdaq Copenhagen
Other stock markets
 10:59:35 2024-05-08 am EDT 		5-day change 1st Jan Change
338 DKK -2.87% Intraday chart for Gubra A/S +14.19% +170.40%
Apr. 17 Gubra Unveils UCN2 as Novel Anti-Obesity Drug Candidate for Healthy Weight Loss CI
Mar. 29 Certain Shares of Gubra A/S are subject to a Lock-Up Agreement Ending on 29-MAR-2024. CI

Valuation

Fiscal Period: December 2023
Capitalization 1 2,036
Enterprise Value (EV) 1 1,650
P/E ratio -42.6 x
Yield -
Capitalization / Revenue 9.93 x
EV / Revenue 8.05 x
EV / EBITDA -36.8 x
EV / FCF -1,358,594,773 x
FCF Yield -0%
Price to Book 4.25 x
Nbr of stocks (in thousands) 16,290
Reference price 2 125.0
Announcement Date 2/28/24
1DKK in Million2DKK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023
Net sales 1 172.3 255.3 199.4 205
EBITDA 1 21.04 94.49 -27.51 -44.79
EBIT 1 15.86 88.67 -29.43 -47.67
Operating Margin 9.21% 34.73% -14.76% -23.25%
Earnings before Tax (EBT) 1 13.68 87.1 6.259 -42.9
Net income 1 12.69 67.94 4.31 -44.52
Net margin 7.37% 26.61% 2.16% -21.72%
EPS 2 97.57 517.5 32.60 -2.935
Free Cash Flow - 51.54 -33.78 -1.215
FCF margin - 20.19% -16.94% -0.59%
FCF Conversion (EBITDA) - 54.54% - -
FCF Conversion (Net income) - 75.86% - -
Dividend per Share 2 50.00 500.0 516.5 -
Announcement Date 2/27/23 2/27/23 2/27/23 2/28/24
1DKK in Million2DKK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023
Net Debt 1 - - - -
Net Cash position 1 8.55 63.3 2.52 386
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - 51.5 -33.8 -1.21
ROE (net income / shareholders' equity) - 58.7% 3.32% -15.1%
ROA (Net income/ Total Assets) - 22.3% -6.51% -6.71%
Assets 1 - 304.8 -66.2 663.7
Book Value Per Share 2 615.0 1,154 819.0 29.40
Cash Flow per Share 2 516.0 882.0 544.0 3.280
Capex 1 7.2 27.2 9.54 5.84
Capex / Sales 4.18% 10.64% 4.79% 2.85%
Announcement Date 2/27/23 2/27/23 2/27/23 2/28/24
1DKK in Million2DKK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
GUBRA A/S Stock Gubra A/S
+170.40% 795M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+2.97% 108B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.21% 104B
ARGENX SE Stock argenx SE
+2.33% 22.33B
BIONTECH SE Stock BioNTech SE
-12.77% 22.19B
GENMAB A/S Stock Genmab A/S
-7.05% 18.69B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.64% 17.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-6.50% 17.64B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.00% 14.05B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.20% 12.51B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. GUBRA Stock
  4. Financials Gubra A/S
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW